home / stock / mdna:cc / mdna:cc quote
Last: | $2.02 |
---|---|
Change Percent: | -3.81% |
Open: | $2.1 |
Close: | $2.10 |
High: | $2.1 |
Low: | $2 |
Volume: | 23,946 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.02 | $2.1 | $2.1 | $2.1 | $2 | 23,946 | 08-02-2022 |
$1.41 | $1.49 | $1.41 | $1.49 | $1.39 | 44,567 | 05-06-2022 |
$1.47 | $1.46 | $1.47 | $1.47 | $1.44 | 7,530 | 05-05-2022 |
$1.46 | $1.49 | $1.46 | $1.49 | $1.4 | 16,085 | 05-04-2022 |
$1.45 | $1.5 | $1.45 | $1.5 | $1.4 | 18,132 | 05-03-2022 |
$1.5 | $1.41 | $1.5 | $1.5 | $1.39 | 20,957 | 05-02-2022 |
$1.42 | $1.5 | $1.42 | $1.5 | $1.39 | 5,938 | 04-29-2022 |
$1.41 | $1.51 | $1.41 | $1.57 | $1.41 | 23,362 | 04-28-2022 |
$1.4 | $1.46 | $1.4 | $1.6 | $1.38 | 71,496 | 04-27-2022 |
$1.35 | $1.47 | $1.35 | $1.47 | $1.35 | 15,715 | 04-26-2022 |
$1.47 | $1.45 | $1.47 | $1.47 | $1.4 | 41,647 | 04-25-2022 |
$1.43 | $1.42 | $1.43 | $1.49 | $1.4 | 36,074 | 04-22-2022 |
$1.4 | $1.47 | $1.4 | $1.47 | $1.38 | 49,684 | 04-21-2022 |
$1.47 | $1.49 | $1.47 | $1.52 | $1.43 | 27,343 | 04-20-2022 |
$1.54 | $1.5 | $1.54 | $1.54 | $1.48 | 7,352 | 04-19-2022 |
$1.49 | $1.56 | $1.49 | $1.56 | $1.47 | 36,958 | 04-18-2022 |
$1.56 | $1.64 | $1.56 | $1.64 | $1.38 | 118,764 | 04-15-2022 |
$1.56 | $1.64 | $1.56 | $1.64 | $1.38 | 118,764 | 04-14-2022 |
$1.53 | $1.57 | $1.53 | $1.6 | $1.5 | 38,338 | 04-13-2022 |
$1.58 | $1.57 | $1.58 | $1.66 | $1.55 | 45,584 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA:CC Stock Symbol:
TSXC Market:
Medicenna Therapeutics Corp. Website:
Melcor Real Estate Investment Trust (MR.UN:CA) is expected to report for Q2 2024 Galleon Gold Corp. (GGO:CA) is expected to report for Q2 2024 Koryx Copper Inc. (KRY:CA) is expected to report for Q3 2024 Medicure Inc. (MPH:CA) is expected to report for Q2 2024 Pinetree Capital Ltd...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...